Compare MSGM & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSGM | HIND |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 15.2M |
| IPO Year | 2020 | 2016 |
| Metric | MSGM | HIND |
|---|---|---|
| Price | $4.32 | $2.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 48.7K | 13.9K |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 252.13 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $741,000.00 | N/A |
| Revenue This Year | $69.73 | N/A |
| Revenue Next Year | $146.81 | N/A |
| P/E Ratio | $78.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.11 | $1.75 |
| 52 Week High | $5.78 | $12.87 |
| Indicator | MSGM | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 45.12 |
| Support Level | $3.64 | $1.99 |
| Resistance Level | $4.48 | $2.36 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 49.83 | 8.00 |
Motorsport Games Inc is a motorsport network company that combines engaging video games with esports competitions and content for racing fans and gamers around the globe. The company has its reportable segments into the development and publishing of interactive racing video games, entertainment content and services, and the organization and facilitation of esports tournaments, competitions, and events for licensed racing games as well as on behalf of third-party video game racing series and other video game publishers. The majority of the revenue is earned from Gaming.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.